Wayne Springate - AIM ImmunoTech Senior Vice President - Operations
| AIM Stock | USD 0.81 0.01 1.90% |
Insider
Wayne Springate is Senior Vice President - Operations of AIM ImmunoTech since 2011.
| Age | 44 |
| Tenure | 15 years |
| Address | 2117 SW Highway 484, Ocala, FL, United States, 34473 |
| Phone | 352 448 7797 |
| Web | https://aimimmuno.com |
Wayne Springate Latest Insider Activity
Tracking and analyzing the buying and selling activities of Wayne Springate against AIM ImmunoTech stock is an integral part of due diligence when investing in AIM ImmunoTech. Wayne Springate insider activity provides valuable insight into whether AIM ImmunoTech is net buyers or sellers over its current business cycle. Note, AIM ImmunoTech insiders must abide by specific rules, including filing SEC forms every time they buy or sell AIM ImmunoTech'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Wayne Springate over a year ago Acquisition by Wayne Springate of 75000 shares of AIM ImmunoTech subject to Rule 16b-3 |
AIM ImmunoTech Management Efficiency
The company has Return on Asset of (0.9542) % which means that on every $100 spent on assets, it lost $0.9542. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (31.3891) %, meaning that it generated no profit with money invested by stockholders. AIM ImmunoTech's management efficiency ratios could be used to measure how well AIM ImmunoTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, AIM ImmunoTech's Return On Capital Employed is very stable compared to the past year. As of the 13th of February 2026, Return On Equity is likely to grow to 12.38, though Return On Tangible Assets are likely to grow to (3.15). At this time, AIM ImmunoTech's Non Current Assets Total are very stable compared to the past year. As of the 13th of February 2026, Intangible Assets is likely to grow to about 3.1 M, while Other Current Assets are likely to drop about 217.4 K.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Lacey | BioLineRx | N/A | |
| Jeffrey Welch | GeoVax Labs | N/A | |
| LLB BSc | BioLineRx | N/A | |
| Liron MBA | BioLineRx | N/A | |
| M MD | Lipocine | 66 | |
| Raziel Fried | BioLineRx | N/A | |
| McKee MD | GeoVax Labs | 72 | |
| CPA CPA | Lipocine | 54 | |
| Logan Morse | Lipocine | 56 | |
| CPA CPA | GeoVax Labs | 62 | |
| Mark Newman | GeoVax Labs | 71 | |
| Advocate Kotler | BioLineRx | 72 | |
| HuiLan Wu | Ainos Inc | 63 | |
| John Esq | Ainos Inc | 57 | |
| Krista Fogarty | Lipocine | 58 | |
| Abi MD | BioLineRx | 47 | |
| Jael MSc | BioLineRx | N/A | |
| CPA CPA | BioLineRx | 49 | |
| CPA MBA | BioLineRx | 62 | |
Management Performance
| Return On Equity | -31.39 | ||||
| Return On Asset | -0.95 |
AIM ImmunoTech Leadership Team
Elected by the shareholders, the AIM ImmunoTech's board of directors comprises two types of representatives: AIM ImmunoTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AIM. The board's role is to monitor AIM ImmunoTech's management team and ensure that shareholders' interests are well served. AIM ImmunoTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AIM ImmunoTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wayne Springate, Senior Vice President - Operations | ||
| III Esq, Exec COO | ||
| Ann Coverly, Director Coordinator | ||
| MBA IV, Chief Officer | ||
| Jodie Pelz, Director Finance | ||
| Stewart Appelrouth, Director | ||
| Ellen Lintal, Chief Financial Officer | ||
| Christopher McAleer, Scientific Officer | ||
| Robert IV, Chief Officer | ||
| Esq JD, CEO Chairman | ||
| David Strayer, Chief Scientific & Medical Officer | ||
| William Mitchell, Chairman of the Board | ||
| Peter Rodino, Executive Director - Governmental Relations, General Counsel | ||
| MD FACP, Member Officer | ||
| Thomas Equels, Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel | ||
| David MD, Chief Director | ||
| Ralph Cavalli, Vice Manufacturing | ||
| IV BA, Chief Officer | ||
| Carol Smith, Chief Officer |
AIM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AIM ImmunoTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -31.39 | ||||
| Return On Asset | -0.95 | ||||
| Operating Margin | (94.12) % | ||||
| Current Valuation | 2.8 M | ||||
| Shares Outstanding | 3.4 M | ||||
| Shares Owned By Insiders | 3.85 % | ||||
| Shares Owned By Institutions | 4.98 % | ||||
| Number Of Shares Shorted | 328.27 K | ||||
| Price To Earning | 12.50 X | ||||
| Price To Book | 2.72 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Will Biotechnology sector continue expanding? Could AIM diversify its offerings? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AIM ImmunoTech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (18.16) | Revenue Per Share | Quarterly Revenue Growth (0.26) | Return On Assets | Return On Equity |
AIM ImmunoTech's market price often diverges from its book value, the accounting figure shown on AIM's balance sheet. Smart investors calculate AIM ImmunoTech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since AIM ImmunoTech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that AIM ImmunoTech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AIM ImmunoTech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.